Immuno-Oncology Therapy Market Size, Share, Trends, Growth and Forecast 2032

Immuno-Oncology Therapy Market

Immuno-Oncology Therapy Market By Therapy Type (Monoclonal Antibodies, Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, and Others), Therapeutic Area (Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Melanoma, Blood Cancer, and Others Cancers), By End-user ( Hospitals, Clinics, Ambulatory Surgical Centers (ASCs), and Cancer Research Institutes) Global Industry Perspective, Comprehensive Analysis and Forecast, 2024-2032

Category: Pharmaceutical Report Format : PDF Pages: 140 Report Code: ZMR-2534 Published Date: Nov-2024 Status : Published
Market Size in 2023 Market Forecast in 2032 CAGR (in %) Base Year
USD 57.83 Billion USD 309.31 Billion 20.48% 2023

Table Of Content

  • Chapter No. 1 Introduction
    • 1.1. Report Description
      • 1.1.1. Purpose of the Report
      • 1.1.2. USP & Key Offerings
    • 1.2. Key Benefits for Stakehulders
    • 1.3. Target Audience
    • 1.4. Report Scope
  • Chapter No. 2 Executive Summary
    • 2.1. Key Findings
      • 2.1.1. Top Investment Pockets
        • 2.1.1.1. Market Attractiveness Analysis, By Therapy Type
        • 2.1.1.2. Market Attractiveness Analysis, By Therapeutic Area
        • 2.1.1.3. Market Attractiveness Analysis, By End-user
        • 2.1.1.4. Market Attractiveness Analysis, By Region
    • 2.2. Market Snapshot
    • 2.3. Global Immuno-onculogy therapy Market, 2016 – 2028 (USD Billion)
    • 2.4. Insights from Primary Respondents
  • Chapter No. 3 COVID 19 Impact Analysis
    • 3.1. Impact Assessment of COVID-19 Pandemic, By Region
      • 3.1.1. North America
      • 3.1.2. Europe
      • 3.1.3. Asia Pacific
      • 3.1.4. Latin America
      • 3.1.5. The Middle-East and Africa
    • 3.2. Quarterly Market Revenue and Forecast by Region 2020 & 2021
    • 3.3. Pre COVID-19 Market Revenue, By Region, 2016-2019 (USD Billion)
    • 3.4. Post COVID-19 Market Revenue, By Region, 2020-2028 (USD Billion)
    • 3.5. Key Strategies Undertaken by Companies to Tackle COVID-19
      • 3.5.1. Company Quarterly Revenue Analysis, 2019 & 2020
    • 3.6. Short Term Dynamics
    • 3.7. Long Term Dynamics
  • Chapter No. 4 Immuno-onculogy therapy Market – Therapy Type Segment Analysis
    • 4.1. Overview
      • 4.1.1. Market Revenue Share, By Therapy Type, 2020 & 2028
    • 4.2. Monoclonal Antibodies
      • 4.2.1. Market Size and Forecast, By Region (USD Billion)
      • 4.2.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.2.3. Key Market Trends, Growth Factors, & Opportunities
    • 4.3. Immune Checkpoint Inhibitors
      • 4.3.1. Market Size and Forecast, By Region (USD Billion)
      • 4.3.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.3.3. Key Market Trends, Growth Factors, & Opportunities
    • 4.4. Immune System Modulators
      • 4.4.1. Market Size and Forecast, By Region (USD Billion)
      • 4.4.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.4.3. Key Market Trends, Growth Factors, & Opportunities
    • 4.5. Cancer Vaccines
      • 4.5.1. Market Size and Forecast, By Region (USD Billion)
      • 4.5.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.5.3. Key Market Trends, Growth Factors, & Opportunities
    • 4.6. Others
      • 4.6.1. Market Size and Forecast, By Region (USD Billion)
      • 4.6.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.6.3. Key Market Trends, Growth Factors, & Opportunities
  • Chapter No. 5 Immuno-onculogy therapy Market – Therapeutic Area Segment Analysis
    • 5.1. Overview
      • 5.1.1. Market Revenue Share, By Therapeutic Area, 2020 & 2028
    • 5.2. Lung Cancer
      • 5.2.1. Market Size and Forecast, By Region (USD Billion)
      • 5.2.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 5.2.3. Key Market Trends, Growth Factors, & Opportunities
    • 5.3. Culorectal Cancer
      • 5.3.1. Market Size and Forecast, By Region (USD Billion)
      • 5.3.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 5.3.3. Key Market Trends, Growth Factors, & Opportunities
      • 5.3.3. Key Market Trends, Growth Factors, & Opportunities
    • 5.4. Breast Cancer
      • 5.4.1. Market Size and Forecast, By Region (USD Billion)
      • 5.4.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 5.4.3. Key Market Trends, Growth Factors, & Opportunities
      • 5.4.3. Key Market Trends, Growth Factors, & Opportunities
    • 5.5. Prostate Cancer
      • 5.5.1. Market Size and Forecast, By Region (USD Billion)
      • 5.5.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 5.5.3. Key Market Trends, Growth Factors, & Opportunities
      • 5.5.3. Key Market Trends, Growth Factors, & Opportunities
    • 5.6. Melanoma
      • 5.6.1. Market Size and Forecast, By Region (USD Billion)
      • 5.6.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 5.6.3. Key Market Trends, Growth Factors, & Opportunities
      • 5.6.3. Key Market Trends, Growth Factors, & Opportunities
    • 5.7. Blood Cancer
      • 5.7.1. Market Size and Forecast, By Region (USD Billion)
      • 5.7.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 5.7.3. Key Market Trends, Growth Factors, & Opportunities
      • 5.7.3. Key Market Trends, Growth Factors, & Opportunities
    • 5.8. Other Cancers
      • 5.8.1. Market Size and Forecast, By Region (USD Billion)
      • 5.8.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 5.8.3. Key Market Trends, Growth Factors, & Opportunities
      • 5.8.3. Key Market Trends, Growth Factors, & Opportunities
  • Chapter No. 6 Immuno-onculogy therapy Market – End-user Segment Analysis
    • 6.1. Overview
      • 6.1.1. Market Revenue Share, By End-user, 2020 & 2028
    • 6.2. Hospitals
      • 6.2.1. Market Size and Forecast, By Region (USD Billion)
      • 6.2.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 6.2.3. Key Market Trends, Growth Factors, & Opportunities
    • 6.3. Clinics
      • 6.3.1. Market Size and Forecast, By Region (USD Billion)
      • 6.3.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 6.3.3. Key Market Trends, Growth Factors, & Opportunities
    • 6.4. Ambulatory Surgical Centers (ASC’s)
      • 6.4.1. Market Size and Forecast, By Region (USD Billion)
      • 6.4.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 6.4.3. Key Market Trends, Growth Factors, & Opportunities
    • 6.5. Cancer Research Institutes
      • 6.4.1. Market Size and Forecast, By Region (USD Billion)
      • 6.4.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 6.4.3. Key Market Trends, Growth Factors, & Opportunities
  • Chapter No. 7 Immuno-onculogy therapy Market – Regional Analysis
    • 7.1. Overview
      • 7.1.1. Global Market Revenue Share, By Region, 2020 & 2028
      • 7.1.2. Global Market Revenue, By Region, 2016 – 2028 (USD Billion)
    • 7.2. North America
      • 7.2.1. North America Market Revenue, By Country, 2016 – 2028 (USD Billion)
      • 7.2.2. North America Market Revenue, By Therapy Type, 2016 – 2028
      • 7.2.3. North America Market Revenue, By Therapeutic Area, 2016 – 2028
      • 7.2.4. North America Market Revenue, By End-user, 2016 – 2028
      • 7.2.5. U.S.
        • 7.2.5.1. U.S. Market Revenue, By Therapy Type, 2016 – 2028
        • 7.2.5.2. U.S. Market Revenue, By Therapeutic Area, 2016 – 2028
        • 7.2.5.3. U.S. Market Revenue, By End-user, 2016 – 2028
      • 7.2.6. Canada
        • 7.2.6.1. Canada Market Revenue, By Therapy Type, 2016 – 2028
        • 7.2.6.2. Canada Market Revenue, By Therapeutic Area, 2016 – 2028
        • 7.2.6.3. Canada Market Revenue, By End-user, 2016 – 2028
      • 7.2.7. Mexico
        • 7.2.7.1. Mexico Market Revenue, By Therapy Type, 2016 – 2028
        • 7.2.7.2. Mexico Market Revenue, By Therapeutic Area, 2016 – 2028
        • 7.2.7.3. Mexico Market Revenue, By End-user, 2016 – 2028
    • 7.3. Europe
      • 7.3.1. Europe Market Revenue, By Country, 2016 – 2028 (USD Billion)
      • 7.3.2. Europe Market Revenue, By Therapy Type, 2016 – 2028
      • 7.3.3. Europe Market Revenue, By Therapeutic Area, 2016 – 2028
      • 7.3.4. Europe Market Revenue, By End-user, 2016 – 2028
      • 7.3.5. Germany
        • 7.3.5.1. Germany Market Revenue, By Therapy Type, 2016 – 2028
        • 7.3.5.2. Germany Market Revenue, By Therapeutic Area, 2016 – 2028
        • 7.3.5.3. Germany Market Revenue, By End-user, 2016 – 2028
      • 7.3.6. France
        • 7.3.6.1. France Market Revenue, By Therapy Type, 2016 – 2028
        • 7.3.6.2. France Market Revenue, By Therapeutic Area, 2016 – 2028
        • 7.3.6.3. France Market Revenue, By End-user, 2016 – 2028
      • 7.3.7. U.K.
        • 7.3.7.1. U.K. Market Revenue, By Therapy Type, 2016 – 2028
        • 7.3.7.2. U.K. Market Revenue, By Therapeutic Area, 2016 – 2028
        • 7.3.7.3. U.K. Market Revenue, By End-user, 2016 – 2028
      • 7.3.8. Italy
        • 7.3.8.1. Italy Market Revenue, By Therapy Type, 2016 – 2028
        • 7.3.8.2. Italy Market Revenue, By Therapeutic Area, 2016 – 2028
        • 7.3.8.3. Italy Market Revenue, By End-user, 2016 – 2028
      • 7.3.9. Spain
        • 7.3.9.1. Spain Market Revenue, By Therapy Type, 2016 – 2028
        • 7.3.9.2. Spain Market Revenue, By Therapeutic Area, 2016 – 2028
        • 7.3.9.3. Spain Market Revenue, By End-user, 2016 – 2028
      • 7.3.10. Rest of Europe
        • 7.3.10.1. Rest of Europe Market Revenue, By Therapy Type, 2016 – 2028
        • 7.3.10.2. Rest of Europe Market Revenue, By Therapeutic Area, 2016 – 2028
        • 7.3.10.3. Rest of Europe Market Revenue, By End-user, 2016 – 2028
    • 7.4. Asia Pacific
      • 7.4.1. Asia Pacific Market Revenue, By Country, 2016 – 2028 (USD Billion)
      • 7.4.2. Asia Pacific Market Revenue, By Therapy Type, 2016 – 2028
      • 7.4.3. Asia Pacific Market Revenue, By Therapeutic Area, 2016 – 2028
      • 7.4.4. Asia Pacific Market Revenue, By End-user, 2016 – 2028
      • 7.4.5. China
        • 7.4.5.1. China Market Revenue, By Therapy Type, 2016 – 2028
        • 7.4.5.2. China Market Revenue, By Therapeutic Area, 2016 – 2028
        • 7.4.5.3. China Market Revenue, By End-user, 2016 – 2028
      • 7.4.6. Japan
        • 7.4.6.1. Japan Market Revenue, By Therapy Type, 2016 – 2028
        • 7.4.6.2. Japan Market Revenue, By Therapeutic Area, 2016 – 2028
        • 7.4.6.3. Japan Market Revenue, By End-user, 2016 – 2028
      • 7.4.7. India
        • 7.4.7.1. India Market Revenue, By Therapy Type, 2016 – 2028
        • 7.4.7.2. India Market Revenue, By Therapeutic Area, 2016 – 2028
        • 7.4.7.3. India Market Revenue, By End-user, 2016 – 2028
      • 7.4.8. South Korea
        • 7.4.8.1. South Korea Market Revenue, By Therapy Type, 2016 – 2028
        • 7.4.8.2. South Korea Market Revenue, By Therapeutic Area, 2016 – 2028
        • 7.4.8.3. South Korea Market Revenue, By End-user, 2016 – 2028
      • 7.4.9. South-East Asia
        • 7.4.9.1. South-East Asia Market Revenue, By Therapy Type, 2016 – 2028
        • 7.4.9.2. South-East Asia Market Revenue, By Therapeutic Area, 2016 – 2028
        • 7.4.9.3. South-East Asia Market Revenue, By End-user, 2016 – 2028
      • 7.4.10. Rest of Asia Pacific
        • 7.4.10.1. Rest of Asia Pacific Market Revenue, By Therapy Type, 2016 – 2028
        • 7.4.10.2. Rest of Asia Pacific Market Revenue, By Therapeutic Area, 2016 – 2028
        • 7.4.10.3. Rest of Asia Pacific Market Revenue, By End-user, 2016 – 2028
    • 7.5. Latin America
      • 7.5.1. Latin America Market Revenue, By Country, 2016 – 2028 (USD Billion)
      • 7.5.2. Latin America Market Revenue, By Therapy Type, 2016 – 2028
      • 7.5.3. Latin America Market Revenue, By Therapeutic Area, 2016 – 2028
      • 7.5.4. Latin America Market Revenue, By End-user, 2016 – 2028
      • 7.5.5. Brazil
        • 7.5.5.1. Brazil Market Revenue, By Therapy Type, 2016 – 2028
        • 7.5.5.2. Brazil Market Revenue, By Therapeutic Area, 2016 – 2028
        • 7.5.5.3. Brazil Market Revenue, By End-user, 2016 – 2028
      • 7.5.6. Argentina
        • 7.5.6.1. Argentina Market Revenue, By Therapy Type, 2016 – 2028
        • 7.5.6.2. Argentina Market Revenue, By Therapeutic Area, 2016 – 2028
        • 7.5.6.3. Argentina Market Revenue, By End-user, 2016 – 2028
      • 7.5.7. Rest of Latin America
        • 7.5.7.1. Rest of Latin America Market Revenue, By Therapy Type, 2016 – 2028
        • 7.5.7.2. Rest of Latin America Market Revenue, By Therapeutic Area, 2016 – 2028
        • 7.5.7.3. Rest of Latin America Market Revenue, By End-user, 2016 – 2028
    • 7.6. The Middle-East and Africa
      • 7.6.1. The Middle-East and Africa Market Revenue, By Country, 2016 – 2028 (USD Billion)
      • 7.6.2. The Middle-East and Africa Market Revenue, By Therapy Type, 2016 – 2028
      • 7.6.3. The Middle-East and Africa Market Revenue, By Therapeutic Area, 2016 – 2028
      • 7.6.4. The Middle-East and Africa Market Revenue, By End-user, 2016 – 2028
      • 7.6.5. GCC Countries
        • 7.6.5.1. GCC Countries Market Revenue, By Therapy Type, 2016 – 2028
        • 7.6.5.2. GCC Countries Market Revenue, By Therapeutic Area, 2016 – 2028
        • 7.6.5.3. GCC Countries Market Revenue, By End-user, 2016 – 2028
      • 7.6.6. South Africa
        • 7.6.6.1. South Africa Market Revenue, By Therapy Type, 2016 – 2028
        • 7.6.6.2. South Africa Market Revenue, By Therapeutic Area, 2016 – 2028
        • 7.6.6.3. South Africa Market Revenue, By End-user, 2016 – 2028
      • 7.6.7. Rest of Middle-East Africa
        • 7.6.7.1. Rest of Middle-East Africa Market Revenue, By Therapy Type, 2016 – 2028
        • 7.6.7.2. Rest of Middle-East Africa Market Revenue, By Therapeutic Area, 2016 – 2028
        • 7.6.7.3. Rest of Middle-East Africa Market Revenue, By End-user, 2016 – 2028
  • Chapter No. 8 Immuno-onculogy therapy Market – Industry Analysis
    • 8.1. Introduction
    • 8.2. Market Drivers
      • 8.2.1. Driving Factor 1 Analysis
      • 8.2.2. Driving Factor 2 Analysis
    • 8.3. Market Restraints
      • 8.3.1. Restraining Factor Analysis
    • 8.4. Market Opportunities
      • 8.4.1. Market Opportunity Analysis
    • 8.5. Porter’s Five Forces Analysis
    • 8.6. PEST Analysis
    • 8.7. Regulatory Landscape
    • 8.8. Therapy Type Landscape
    • 8.9. Regional Market Trends
      • 8.9.1. North America
      • 8.9.2. Europe
      • 8.9.3. Asia Pacific
      • 8.9.4. Latin America
      • 8.9.5. The Middle-East and Africa
    • 8.10. Pricing Analysis
    • 8.11. Value Chain Analysis
    • 8.12. Downstream Buyers
    • 8.13. Distributors/Traders List
  • Chapter No. 9 Competitive Landscape
    • 9.1. Company Market Share Analysis – 2019
      • 9.1.1. Global Immuno-onculogy therapy Market: Company Market Share, 2019
      • 9.1.2. Global Immuno-onculogy therapy Market, Company Market Revenue, 2016 – 2019 (USD Billion)
      • 9.1.3. Global Immuno-onculogy therapy Market, Company Y-o-Y Growth, 2017 – 2019 (%)
      • 9.1.4. Global Immuno-onculogy therapy Market: Radar Determinant Chart, 2019
    • 9.2. Strategic Developments
      • 9.2.1. Acquisitions & Mergers
      • 9.2.2. New Product Launch
      • 9.2.3. Regional Expansion
    • 9.3. Company Strategic Developments – Heat Map Analysis
  • Chapter No. 10 Company Profiles
    • 10.1. Amgen, Inc.
      • 10.1.1. Company Overview
      • 10.1.2. Key Executives
      • 10.1.3. Product Portfolio
      • 10.1.4. Financial Overview
      • 10.1.5. Operating Business Segments
      • 10.1.6. Business Performance
      • 10.1.7. Recent Developments
    • 10.2. SITA
    • 10.3. AstraZeneca Plc.
    • 10.4. Bristul-Myers Squibb Company
    • 10.5. Eli-Lilly and Company
    • 10.6. F.Hoffmann-La Roche Ltd.
    • 10.7. GlaxoSmithKline Plc.
    • 10.8. Janssen Biotech, Inc.
    • 10.9. Merck and Co.
    • 10.10. Novartis AG
    • 10.11. Pfizer, Inc.
    • 10.12. Sanofi
    • 10.13. Spectrum Pharmaceuticals
    • 10.14. Takeda Pharmaceuticals
  • Chapter No. 11 Marketing Strategy Analysis
    • 11.1. Marketing Channel
    • 11.2. Direct Marketing
    • 11.3. Indirect Marketing
    • 11.4. Marketing Channel Development Trends
    • 11.5. Economic/Pulitical Therapeutic Area Change
  • Chapter No. 12 Research Methodology
    • 12.1. Research Methodology
    • 12.2. Phase I - Secondary Research
    • 12.3. Phase II - Data Modeling
      • 12.3.1. Company Share Analysis Model
      • 12.3.2. Revenue Based Modeling
    • 12.4. Phase III - Primary Research
    • 12.5. Research Limitations
      • 12.5.1. Assumptions

Table Of Figures

List of Figures 

FIG NO. 1. Market Attractiveness Analysis, By Therapy Type
FIG NO. 2. Market Attractiveness Analysis, By Therapeutic Area
FIG NO. 4. Market Attractiveness Analysis, By Region
FIG NO. 5. Global Immuno-oncology therapy Market Revenue, 2016 – 2028 (USD Billion)
FIG NO. 6. Impact of COVID-19 Pandemic in North America Countries
FIG NO. 7. Market Revenue Share, By Therapy Type, 2020 & 2028 
FIG NO. 8. Global Immuno-oncology therapy Market for Monoclonal Antibodies, Revenue (USD Billion) 2016 – 2028
FIG NO. 9. Comparative Revenue Analysis of Immuno-oncology therapy Market for Monoclonal Antibodies, By Country, 2020 & 2028
FIG NO. 10. Global Immuno-oncology therapy Market for Immune Checkpoint Inhibitors, Revenue (USD Billion) 2016 – 2028
FIG NO. 11. Comparative Revenue Analysis of Immuno-oncology therapy Market for Immune Checkpoint Inhibitors, By Country, 2020 & 2028
FIG NO. 12. Global Immuno-oncology therapy Market for Immune System Modulators, Revenue (USD Billion) 2016 – 2028
FIG NO. 13. Comparative Revenue Analysis of Immuno-oncology therapy Market for Immune System Modulators, By Country, 2020 & 2028
FIG NO. 15. Global Immuno-oncology therapy Market for Cancer Vaccines, Revenue (USD Billion) 2016 – 2028
FIG NO. 16. Comparative Revenue Analysis of Immuno-oncology therapy Market for Cancer Vaccines, By Country, 2020 & 2028
FIG NO. 17. Global Immuno-oncology therapy Market for Others, Revenue (USD Billion) 2016 – 2028
FIG NO. 18. Comparative Revenue Analysis of Immuno-oncology therapy Market for Others, By Country, 2020 & 2028
FIG NO. 19. Market Revenue Share, By Therapeutic Area, 2020 & 2028
FIG NO. 20. Global Immuno-oncology therapy Market for Lung Cancer, Revenue (USD Billion) 2016 – 2028
FIG NO. 21. Comparative Revenue Analysis of Immuno-oncology therapy Market for Lung Cancer, By Country, 2020 & 2028
FIG NO. 22. Global Immuno-oncology therapy Market for Colorectal Cancer, Revenue (USD Billion) 2016 – 2028
FIG NO. 23. Comparative Revenue Analysis of Immuno-oncology therapy Market for Colorectal Cancer, By Country, 2020 & 2028
FIG NO. 24. Global Immuno-oncology therapy Market for Breast Cancer, Revenue (USD Billion) 2016 – 2028
FIG NO. 25. Comparative Revenue Analysis of Immuno-oncology therapy Market for Breast Cancer, By Country, 2020 & 2028
FIG NO. 26. Global Immuno-oncology therapy Market for Prostate Cancer, Revenue (USD Billion) 2016 – 2028
FIG NO. 27. Comparative Revenue Analysis of Immuno-oncology therapy Market for Prostate Cancer, By Country, 2020 & 2028
FIG NO. 28. Global Immuno-oncology therapy Market for Melanoma, Revenue (USD Billion) 2016 – 2028
FIG NO. 29. Comparative Revenue Analysis of Immuno-oncology therapy Market for Melanoma, By Country, 2020 & 2028
FIG NO. 30. Global Immuno-oncology therapy Market for Blood Cancer, Revenue (USD Billion) 2016 – 2028
FIG NO. 31. Comparative Revenue Analysis of Immuno-oncology therapy Market for Blood Cancer, By Country, 2020 & 2028
FIG NO. 32. Global Immuno-oncology therapy Market for Other Cancers, Revenue (USD Billion) 2016 – 2028
FIG NO. 33. Comparative Revenue Analysis of Immuno-oncology therapy Market for Other Cancers, By Country, 2020 & 2028
FIG NO. 34. Market Revenue Share, By  End-user, 2020 & 2028
FIG NO. 35. Global Immuno-oncology therapy Market for  Hospitals, Revenue (USD Billion) 2016 – 2028
FIG NO. 36. Comparative Revenue Analysis of Immuno-oncology therapy Market for  Hospitals, By Country, 2020 & 2028
FIG NO. 37. Global Immuno-oncology therapy Market for  Clinics, Revenue (USD Billion) 2016 – 2028
FIG NO. 38. Comparative Revenue Analysis of Immuno-oncology therapy Market for  Clinics, By Country, 2020 & 2028
FIG NO. 39. Global Immuno-oncology therapy Market for  Ambulatory Surgical Centers (ASC’s), Revenue (USD Billion) 2016 – 2028
FIG NO. 40. Comparative Revenue Analysis of Immuno-oncology therapy Market for  Ambulatory Surgical Centers (ASC’s), By Country, 2020 & 2028
FIG NO. 41. Global Immuno-oncology therapy Market for Cancer Research Institutes, Revenue (USD Billion) 2016 – 2028
FIG NO. 42. Comparative Revenue Analysis of Immuno-oncology therapy Market for Cancer Research Institutes, By Country, 2020 & 2028
FIG NO. 43. Global Immuno-oncology therapy Market Revenue Share, By Region, 2020 & 2028
FIG NO. 44. North America Immuno-oncology therapy Market Revenue, 2016 - 2028 (USD Billion)
FIG NO. 45. Porter’s Five Forces Analysis for Global Immuno-oncology therapy Market
FIG NO. 46. PEST Analysis for Global Immuno-oncology therapy Market
FIG NO. 47. Pricing Analysis for Global Immuno-oncology therapy Market
FIG NO. 48. Value Chain Analysis for Global Immuno-oncology therapy Market
FIG NO. 49. Company Share Analysis, 2019
FIG NO. 50. Radar Determinant Chart, 2019
FIG NO. 51. Company Strategic Developments – Heat Map Analysis
FIG NO. 52. Amgen, Inc. Business Segment Revenue Share, 2020 (%)
FIG NO. 53. Amgen, Inc. Geographical Segment Revenue Share, 2020 (%)
FIG NO. 54. Market Channels
FIG NO. 55. Marketing Channel Development Trend
FIG NO. 56. Growth in World Gross Product, 2008-2018
FIG NO. 57. Research Methodology – Detailed View
FIG NO. 58. Research Methodology
 


Table Of Tables

List of Tables 

TABLE NO. 1. Global Immuno-oncology therapy Market: Snapshot
TABLE NO. 2. Quarterly Immuno-oncology therapy Market Revenue by Region, 2020
TABLE NO. 3. Quarterly Immuno-oncology therapy Market Revenue Forecast by Region, 2021
TABLE NO. 4. Pre COVID-19 Market Revenue, By Region, 2016-2019 (USD Billion)
TABLE NO. 5. Post COVID-19 Market Revenue, By Region, 2020-2028 (USD Billion)
TABLE NO. 6. Global Immuno-oncology therapy Market for Monoclonal Antibodies, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 7. Global Immuno-oncology therapy Market for Immune Checkpoint Inhibitors, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 8. Global Immuno-oncology therapy Market for Immune System Modulators, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 9. Global Immuno-oncology therapy Market for Cancer Vaccines, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 10. Global Immuno-oncology therapy Market for Others, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 11. Global Immuno-oncology therapy Market for Lung Cancer, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 12. Global Immuno-oncology therapy Market for Colorectal Cancer, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 13. Global Immuno-oncology therapy Market for Breast Cancer, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 14. Global Immuno-oncology therapy Market for Prostate Cancer, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 15. Global Immuno-oncology therapy Market for Melanoma, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 16. Global Immuno-oncology therapy Market for Blood Cancer, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 17. Global Immuno-oncology therapy Market for Other Cancers, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 18. Global Immuno-oncology therapy Market for  Hospitals, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 19. Global Immuno-oncology therapy Market for  Clinics, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 20. Global Immuno-oncology therapy Market for  Ambulatory Surgical Centers (ASC’s), by Region, 2016 – 2028 (USD Billion)
TABLE NO. 21. Global Immuno-oncology therapy Market for Cancer Research Institutes, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 22. G6obal Immuno-oncology therapy Market Revenue, By Region, 2016 – 2028 (USD Billion)
TABLE NO. 23. North America Immuno-oncology therapy Market Revenue, By Country, 2016 – 2028 (USD Billion)
TABLE NO. 24. North America Immuno-oncology therapy Market Revenue, By Therapy Type, 2016 – 2028 (USD Billion)
TABLE NO. 25. North America Immuno-oncology therapy Market Revenue, By Therapeutic Area, 2016 – 2028 (USD Billion)
TABLE NO. 26. North America Immuno-oncology therapy Market Revenue, By  End-user, 2016 – 2028 (USD Billion)
TABLE NO. 27. U.S. Immuno-oncology therapy Market Revenue, By Therapy Type, 2016 – 2028 (USD Billion)
TABLE NO. 28. U.S. Immuno-oncology therapy Market Revenue, By Therapeutic Area, 2016 – 2028 (USD Billion)
TABLE NO. 29. U.S. Immuno-oncology therapy Market Revenue, By  End-user, 2016 – 2028 (USD Billion)
TABLE NO. 30. Canada Immuno-oncology therapy Market Revenue, By Therapy Type, 2016 – 2028 (USD Billion)
TABLE NO. 31. Canada Immuno-oncology therapy Market Revenue, By Therapeutic Area, 2016 – 2028 (USD Billion)
TABLE NO. 32. Canada Immuno-oncology therapy Market Revenue, By  End-user, 2016 – 2028 (USD Billion)
TABLE NO. 33. Mexico Immuno-oncology therapy Market Revenue, By Therapy Type, 2016 – 2028 (USD Billion) 
TABLE NO. 34. Mexico Immuno-oncology therapy Market Revenue, By Therapeutic Area, 2016 – 2028 (USD Billion)
TABLE NO. 35. Mexico Immuno-oncology therapy Market Revenue, By  End-user, 2016 – 2028 (USD Billion)
TABLE NO. 36. Drivers for the Immuno-oncology therapy Market: Impact Analysis
TABLE NO. 37. Restraints for the Immuno-oncology therapy Market: Impact Analysis
TABLE NO. 38. Major Buyers of Immuno-oncology therapy 
TABLE NO. 39. Distributors/Traders List of Immuno-oncology therapy 
TABLE NO. 40. Global Immuno-oncology therapy Market, Company Market Revenue, 2016 – 2019 (USD Billion)
TABLE NO. 41. Global Immuno-oncology therapy Market, Company Y-o-Y Growth, 2017 – 2019 (USD Billion)
  
 

Methodology

FrequentlyAsked Questions

Immuno-Oncology Therapy Market market size valued at US$ 57.83 Billion in 2023

Immuno-Oncology Therapy Market market size valued at US$ 57.83 Billion in 2023, set to reach US$ 309.31 Billion by 2032 at a CAGR of about 20.48% from 2024 to 2032

Some of the key factors driving the global Immuno-oncology therapy market growth are rising R&D in cancer immunotherapy and a paradigm shift from traditional chemotherapies to immunotherapies.

North America is anticipated to remain the leading region over the forecast period. Rising incidence of the disease, increasing ease of access to modern therapeutics coupled with expanding geriatric population is propelling the market in this region.

The major players operating in the immuno-oncology therapy market are Amgen, Inc., AstraZeneca Plc., Bristol-Myers Squibb Company, Eli-Lilly and Company, F.Hoffmann-La Roche Ltd., GlaxoSmithKline Plc., Janssen Biotech, Inc., Merck and Co., Novartis AG, Pfizer, Inc., Sanofi, Spectrum Pharmaceuticals and Takeda Pharmaceuticals among others.

Choose License Type

  • zion payment modes

List of Contents

Market InsightsMarket OverviewGrowth FactorsReport ScopeSegment Analysis PreviewRegion Analysis Preview Key Market Players Competitive LandscapeThe global Immuno-oncology therapy market is segmented as follows:

RelatedNews

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008

Contact #

US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

twitter

Industry Press Release

We Accept

We have secured system to process your transaction.

  • payment methods

How it Works?

Our Company

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed